CIK 0001528287
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
NeuroPace Inc
Sign in to watch- Ticker
- NPCE
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 223550230
- Phone
- +1 650-237-2700
- Business address
- 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-04 | Ridley Irina General Counsel and Secretary | Grant or award | +5,681 | 8,033 | ||
| 2021-06-04 | Ridley Irina General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +11,363 | 11,363 | ||
| 2021-04-26 | Fischer Frank M Director | Conversion | +472,366 | 565,657 | ||
| 2021-04-26 | Fischer Frank M Director | Conversion · Series A' Preferred Stock | −21,486 | 0 | ||
| 2021-04-26 | Fischer Frank M Director | Conversion · Series B' Preferred Stock | −450,880 | 0 | ||
| 2021-04-26 | ORBIMED ADVISORS LLC 10% owner | Conversion | +3,777,281 | 4,012,281 | ||
| 2021-04-26 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series A' Preferred Stock | −171,895 | 0 | ||
| 2021-04-26 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series B' Preferred Stock | −3,605,386 | 0 | ||
| 2021-04-26 | Norton Evan Director | Conversion | +3,454,422 | 4,042,657 | ||
| 2021-04-26 | Norton Evan Director | Conversion · Series B' Preferred Stock | −3,454,422 | 0 | ||
| 2021-04-26 | Accelmed Partners II L.P. 10% owner | Conversion | +3,454,422 | 4,042,657 | ||
| 2021-04-26 | Accelmed Partners II L.P. 10% owner | Conversion · Series B' Preferred Stock | +3,454,422 | 3,454,422 | ||
| 2021-04-26 | Garfield Greg Shaw Director | Conversion | +18,891 | 18,891 | ||
| 2021-04-26 | Garfield Greg Shaw Director | Conversion | +5,595,493 | 5,614,384 | ||
| 2021-04-26 | Garfield Greg Shaw Director | Conversion · Series A' Preferred Stock | −859 | 0 | ||
| 2021-04-26 | Garfield Greg Shaw Director | Conversion · Series B' Preferred Stock | −18,032 | 0 | ||
| 2021-04-26 | Garfield Greg Shaw Director | Conversion · Series A' Preferred Stock | −323,591 | 0 | ||
| 2021-04-26 | Garfield Greg Shaw Director | Conversion · Series B' Preferred Stock | −5,271,902 | 0 | ||
| 2021-04-26 | Favet Michael Chief Executive Officer | Conversion | +7,562 | 7,562 | ||
| 2021-04-26 | Favet Michael Chief Executive Officer | Grant or award | +15,385 | $0.03 | $462 | 22,947 |
Page 17 of 19 · 362 trades